...Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs. I'm really pleased to have, with us, Clay Siegall, who's the President and CEO of Immunome. So to start here, Clay: you formed this company, maybe, you could just level set for everyone in the room who isn't as familiar, with regard to your strategy; your pipeline; and, really, the key focus points you want us to look at in the second half of the year and beyond, as you look to execute across the overall company. Clay Siegall ...